Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2022
HR-Positive/HER2-Negative Breast Cancer
HR-Positive/HER2-Negative Breast Cancer
Analysis of the Randomized STIC CTC Trial in ER-Positive/HER2-Negative Metastatic Breast Cancer: Overall Survival Findings
SABCS 2022
Circulating tumor cell count found to provide utility in treatment selection decision-making.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Elacestrant in Postmenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer: Findings from the SOLTI-1905-ELIPSE Trial
SABCS 2022
Preoperative treatment with elacestrant is associated with relevant biological and molecular responses.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Maintenance Ribociclib and ET Following First-Line Chemotherapy in HR-Positive/HER2-Negative Metastatic Breast Cancer: Findings from the Phase 2 AMICA Trial
SABCS 2022
Ribociclib plus ET shows promising efficacy as maintenance therapy in patients with HR-positive/HER2-negative metastatic breast cancer.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Preoperative Ribociclib and Letrozole versus Chemotherapy in HR-Positive/HER2-Negative Breast Cancer: Findings from a Correlative Analysis of the Phase 2 1402-SOLTI/CORALLEEN Trial Study
SABCS 2022
Ribociclib in combination with letrozole induces potent antiproliferative effects in comparison to chemotherapy in patients with HR-positive/HER2-negative breast cancer.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
CDK Inhibition in ER-Positive/HER2-Negative Metastatic Breast Cancer: Real-World Evidence of the Risk of Disease Progression on First-Line Treatment
SABCS 2022
No significant differences in PFS were found between abemaciclib, palbociclib, and ribociclib in a real-world setting.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Patient-Reported Outcomes and Progression-Free Survival Findings from the 5th Interim Analysis of the RIBANNA Trial in Patients with HR-Positive/HER2-Negative Advanced Breast Cancer
SABCS 2022
Interim analysis of the RIBANNA trial demonstrates that ribociclib provides a meaningful PFS benefit and maintains QOL in patients with HR-positive/HER2-negative advanced breast cancer.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Pooled Analysis of Post-Progression Treatments after Ribociclib in the MONALEESA-2, -3, and -7 Trials in Patients with HR-Positive/HER2-Negative Advanced Breast Cancer
SABCS 2022
Post-progression targeted therapy after ribociclib found to result in increased duration of therapy.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Ribociclib-Derived Resistance Mutations: ctDNA Findings from the MONALEESA-2, -3, and -7 Trials
SABCS 2022
Comprehensive analysis of acquired resistance mutations in patients with HR-positive/HER2-negative advanced breast cancer post-CDK4/6 inhibitor and endocrine therapy is the largest to date.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Pooled Analysis of Gene Expression and Associated Treatment Response in the MONALEESA-2, -3, and -7 Trials
SABCS 2022
Results from the MONALEESA trials show that PFS benefit with ribociclib in combination with endocrine therapy found to be consistent regardless of expression levels of most cell cycle genes.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Comparison of Progression-Free Survival from the MONALEESA and RIBANNA Trials in Patients with HR-Positive/HER2-Negative Advanced Breast Cancer
SABCS 2022
Analysis from the MONALEESA and RIBANNA trials in patients with HR-positive/HER2-negative advanced breast cancer finds differences in PFS among patients treated with ribociclib in combination with endocrine therapy among MONALEESA-like subgroups.
Read More ›
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us